TACT411

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

TACT411
Clinical data
Other namesTACT-411
Drug classMonoamine transporter modulator; Serotonin 5-HT1B receptor modulator
Identifiers
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).

TACT411 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.[1][2] It is being developed by Tactogen.[1][2] As of the first quarter of 2025, the drug is in the preclinical research stage of development.[1][2] The exact chemical structure of TACT411 does not yet appear to have been disclosed, but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB.[3]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Tactogen 
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://70.231.62.181/index.php?title=TACT411&oldid=20972875"